Cooley advised Akeso, Inc. on the offering. Akeso, Inc. (Hong Kong Exchange code: 9926.HK), a commercial-stage biopharmaceutical company, announced its HK$1.2 billion (appr. USD$153.29 million) follow-on public...
Akeso’s HK$1.2 Billion Follow-On Offering
Laekna’s HK$791 Million Initial Public Offering
Davis Polk, Jingtian & Gongcheng and Harney Westwood advised Laekna, while Cooley and Commerce & Finance Law Offices advised the sole sponsor and the underwriters. Laekna,...